Percy F. Sumariwalla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Percy F. Sumariwalla has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Marc Feldmann
Imperial College London, London, UK
2 shared publications Anna K. Andersson
Imperial College London, London, UK
1 shared publicationB. M. J. Foxwell
Kennedy Institute of Rheumatology, Imperial College London, London, UK and Theracos Inc., Sunnyvale, CA, USA
1 shared publicationBirgitte Ursø
Novo Nordisk, Måløv, Denmark
1 shared publication- Brett Jorgensen
Receptor BioLogix, Inc., Palo Alto, CA 94303, USA
1 shared publication C. D. Palmer
Kennedy Institute of Rheumatology, Imperial College London, London, UK and Theracos Inc., Sunnyvale, CA, USA
1 shared publication
Latest Publications
- Open Access
- 26 May 2011
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (9) , 2617-2629
Blockade of NKG2D ameliorates disease in mice with collagen‐induced arthritis: A potential pathogenic role in chronic inflammatory arthritis
Objective To assess the role of the activating receptor NKG2D in arthritis. Methods Levels of NKG2D and its ligands were determined by fluorescence‐activated cell sorting, real‐time polymerase chain reaction, and immunohistochemistry in rheumatoid arthritis (RA) synovial membrane tissue and in paw tissue from arthritic mice. Arthritis was induced in DBA/1 mice by immunization with type II collagen, and mice were treated intraperitoneally with a blocking anti‐NKG2D antibody (CX5) on days 1, 5, and 8 after clinical onset and were monitored for 10 days. Results We demonstrated expression of NKG2D and its ligands on human RA synovial cells and extended this finding to the paws of arthritic mice. Expression of messenger RNA for the NKG2D ligand Rae‐1 was up‐regulated, and NKG2D was present predominantly on natural killer (NK) and CD4+ T cells, in arthritic paw cell isolates. NKG2D was down‐modulated during the progression of collagen‐induced arthritis (CIA). NKG2D expression in arthritic paws was demonstrated by immunohistochemistry. Blockade of NKG2D ameliorated established CIA, with significant reductions in clinical scores and paw swelling. Histologic analysis of arthritic joints from anti‐NKG2D–treated mice demonstrated significant joint protection, compared with control mice. Moreover, anti‐NKG2D treatment significantly reduced both interleukin‐17 production from CD4+ T cells in arthritic paws and splenic NK cell cytotoxic effector functions in vivo and in vitro. Conclusion Our findings indicate that blockade of NKG2D in a murine model and in human explants has beneficial therapeutic potential that merits further investigation in RA.
- 26 May 2011
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (9) , 2617-2629
Open AccessBlockade of NKG2D ameliorates disease in mice with collagen‐induced arthritis: A potential pathogenic role in chronic inflammatory arthritis
Objective To assess the role of the activating receptor NKG2D in arthritis. Methods Levels of NKG2D and its ligands were determined by fluorescence‐activated cell sorting, real‐time polymerase chain reaction, and immunohistochemistry in rheumatoid arthritis (RA) synovial membrane tissue and in paw tissue from arthritic mice. Arthritis was induced in DBA/1 mice by immunization with type II collagen, and mice were treated intraperitoneally with a blocking anti‐NKG2D antibody (CX5) on days 1, 5, and 8 after clinical onset and were monitored for 10 days. Results We demonstrated expression of NKG2D and its ligands on human RA synovial cells and extended this finding to the paws of arthritic mice. Expression of messenger RNA for the NKG2D ligand Rae‐1 was up‐regulated, and NKG2D was present predominantly on natural killer (NK) and CD4+ T cells, in arthritic paw cell isolates. NKG2D was down‐modulated during the progression of collagen‐induced arthritis (CIA). NKG2D expression in arthritic paws was demonstrated by immunohistochemistry. Blockade of NKG2D ameliorated established CIA, with significant reductions in clinical scores and paw swelling. Histologic analysis of arthritic joints from anti‐NKG2D–treated mice demonstrated significant joint protection, compared with control mice. Moreover, anti‐NKG2D treatment significantly reduced both interleukin‐17 production from CD4+ T cells in arthritic paws and splenic NK cell cytotoxic effector functions in vivo and in vitro. Conclusion Our findings indicate that blockade of NKG2D in a murine model and in human explants has beneficial therapeutic potential that merits further investigation in RA.
- Open Access
- 17 November 2008
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 48 (1) , 32-38
Suppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717
Objectives. To evaluate the clinical efficacy of a novel synthetic peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, CLX-090717, in several in vitro cell culture systems and murine CIA, an experimental model of RA. Methods. Peripheral blood monocytes purified by elutriation, and rheumatoid synovial cells isolated from clinical tissue were cultured with CLX-090717 and TNF-α release was measured. Molecular mechanism of action was analysed by western blotting and electrophoretic mobility shift assay. Thioglycollate-elicited murine peritoneal macrophages were cultured with CLX-090717 and lipopolysaccharide (LPS)-induced TNF-α release was assayed. Therapeutic studies were done in mice with established arthritis by evaluating clinical parameters and histology. In addition, type II collagen response of lymphocytes from mice with CIA was examined. Results. CLX-090717 significantly inhibited spontaneous TNF-α release by RA synovial membrane cells, as well as LPS-induced TNF-α release from human and murine monocytic cells. Inhibition of TNF-α in monocytes was mediated partially through a nuclear factor-κB (NF-κB)-dependent pathway, as judged by sustained levels of IκBα in cytosolic extracts and a reduced level of LPS-induced NF-κB activity in nuclear extracts. CLX-090717 reduced clinical signs of arthritis and damage to joint architecture when administered therapeutically to arthritic mice. Mechanisms of action in CIA involved the reduction in proliferation of arthritic lymphocytes to antigen in vitro as well as reduced TNF-α release. Conclusions. Our data suggest that the synthetic compound CLX-090717 has potential as a small molecular weight anti-inflammatory therapeutic for chronic inflammatory conditions.
- 17 November 2008
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 48 (1) , 32-38
Open AccessSuppression of tumour necrosis factor production from mononuclear cells by a novel synthetic compound, CLX-090717
Objectives. To evaluate the clinical efficacy of a novel synthetic peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, CLX-090717, in several in vitro cell culture systems and murine CIA, an experimental model of RA. Methods. Peripheral blood monocytes purified by elutriation, and rheumatoid synovial cells isolated from clinical tissue were cultured with CLX-090717 and TNF-α release was measured. Molecular mechanism of action was analysed by western blotting and electrophoretic mobility shift assay. Thioglycollate-elicited murine peritoneal macrophages were cultured with CLX-090717 and lipopolysaccharide (LPS)-induced TNF-α release was assayed. Therapeutic studies were done in mice with established arthritis by evaluating clinical parameters and histology. In addition, type II collagen response of lymphocytes from mice with CIA was examined. Results. CLX-090717 significantly inhibited spontaneous TNF-α release by RA synovial membrane cells, as well as LPS-induced TNF-α release from human and murine monocytic cells. Inhibition of TNF-α in monocytes was mediated partially through a nuclear factor-κB (NF-κB)-dependent pathway, as judged by sustained levels of IκBα in cytosolic extracts and a reduced level of LPS-induced NF-κB activity in nuclear extracts. CLX-090717 reduced clinical signs of arthritis and damage to joint architecture when administered therapeutically to arthritic mice. Mechanisms of action in CIA involved the reduction in proliferation of arthritic lymphocytes to antigen in vitro as well as reduced TNF-α release. Conclusions. Our data suggest that the synthetic compound CLX-090717 has potential as a small molecular weight anti-inflammatory therapeutic for chronic inflammatory conditions.
- Open Access
- 29 September 2008
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (10) , 3071-3080
Antagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen‐induced arthritis
Objective: To evaluate the therapeutic potential of the human epidermal growth factor receptor (HER) family inhibitor, herstatin, in an animal model of arthritis.Methods: Constructs of herstatin and modified tissue plasminogen activator (tPA)–herstatin were expressed in HEK 293T cells, and secreted protein was analyzed by Western blotting. Tissue PA–herstatin adenovirus (Ad‐tPA‐Her) was prepared, and titers established. Gene expression of Ad‐tPA‐Her was determined by polymerase chain reaction using HeLa cells. Pharmacokinetics of gene and protein expression in vivo in liver tissue and serum samples were confirmed via intravenous administration of Ad‐tPA‐Her. Clinical signs of disease were monitored in arthritic DBA/1 mice after therapeutic administration of Ad‐tPA‐Her, and histologic analysis of hind foot specimens was performed.Results: Native herstatin was not secreted in supernatants, while modified tPA‐herstatin was detected in abundance. HeLa cells stably expressed the tPA‐herstatin gene when infected with virus. Additionally, tPA‐herstatin gene and protein expression was observed over time in mice treated with virus. Importantly, Ad‐tPA‐Her, when administered therapeutically to arthritic mice, controlled clinical and histologic signs of disease and reduced the number of joints with severe damage.Conclusion: Our results support the notion that the human epidermal growth factor receptor family has a role in the progression of collagen‐induced arthritis. The novel tPA‐herstatin fusion protein could be used as an effective therapeutic tool for control of inflammatory disorders involving an angiogenic component.
- 29 September 2008
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (10) , 3071-3080
Open AccessAntagonism of the human epidermal growth factor receptor family controls disease severity in murine collagen‐induced arthritis
Objective: To evaluate the therapeutic potential of the human epidermal growth factor receptor (HER) family inhibitor, herstatin, in an animal model of arthritis.Methods: Constructs of herstatin and modified tissue plasminogen activator (tPA)–herstatin were expressed in HEK 293T cells, and secreted protein was analyzed by Western blotting. Tissue PA–herstatin adenovirus (Ad‐tPA‐Her) was prepared, and titers established. Gene expression of Ad‐tPA‐Her was determined by polymerase chain reaction using HeLa cells. Pharmacokinetics of gene and protein expression in vivo in liver tissue and serum samples were confirmed via intravenous administration of Ad‐tPA‐Her. Clinical signs of disease were monitored in arthritic DBA/1 mice after therapeutic administration of Ad‐tPA‐Her, and histologic analysis of hind foot specimens was performed.Results: Native herstatin was not secreted in supernatants, while modified tPA‐herstatin was detected in abundance. HeLa cells stably expressed the tPA‐herstatin gene when infected with virus. Additionally, tPA‐herstatin gene and protein expression was observed over time in mice treated with virus. Importantly, Ad‐tPA‐Her, when administered therapeutically to arthritic mice, controlled clinical and histologic signs of disease and reduced the number of joints with severe damage.Conclusion: Our results support the notion that the human epidermal growth factor receptor family has a role in the progression of collagen‐induced arthritis. The novel tPA‐herstatin fusion protein could be used as an effective therapeutic tool for control of inflammatory disorders involving an angiogenic component.
- Open Access
- 1 July 2008
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 10 (4) , R73
Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis
Introduction: Despite the advent of biological therapies for the treatment of rheumatoid arthritis, there is a compelling need to develop alternative therapeutic targets for nonresponders to existing treatments. Soluble receptors occur naturallyin vivo, such as the splice variant of the cell surface receptor for vascular endothelial growth factor (VEGF) – a key regulator of angiogenesis in rheumatoid arthritis. Bioinformatics analyses predict that the majority of human genes undergo alternative splicing, generating proteins – many of which may have regulatory functions. The objective of the present study was to identify alternative splice variants (ASV) from cell surface receptor genes, and to determine whether the novel proteins encoded exert therapeutic activity in anin vivomodel of arthritis.Methods: To identify novel splice variants, we performed RT-PCR using an mRNA pool representing major human tissue types and tumors. Novel ASV were identified by alignment of each cloned sequence to its respective genomic sequence in comparison with full-length transcripts. To test whether these ASV have biologic activity, we characterized a subset of them for ligand binding, and for efficacy in an animal model of arthritis. Thein vivostudy was accomplished using adenoviruses expressing secreted ASV.Results: We cloned 60 novel human ASV from 21 genes, encoding cell surface receptors – many of which are known to be important in the regulation of angiogenesis. The ASV were characterized by exon extension, intron retention and alternative exon utilization. Efficient expression and secretion of selected ASV – corresponding to VEGF receptor type 1, VEGF receptor type 2, VEGF receptor type 3, angiopoietin receptor Tie1, Met (receptor for hepatocyte growth factor), colony-stimulating factor 1 receptor, platelet-derived growth factor receptor beta, fibroblast growth factor receptor 1, Kit, and RAGE – was demonstrated, together with binding to their cognate ligands. Importantly, ASV derived from VEGF receptor type 1 and Tie1, and to a lesser extent from VEGF receptor type 2 and fibroblast growth factor receptor 1, reduced clinical signs of arthritisin vivo. The reduction was paralleled by decreased joint inflammation and destruction.Conclusion: The present study shows that unique ASV derived from receptors that play key roles in angiogenesis – namely, VEGF receptor type 1 and, for the first time, Tie1 – can markedly reduce arthritis severity. More broadly, our results demonstrate that ASV are a source of novel proteins with therapeutic potential in diseases in which angiogenesis and cellular hyperplasia play a central role, such as rheumatoid arthritis.
- 1 July 2008
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 10 (4) , R73
Open AccessNovel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis
Introduction: Despite the advent of biological therapies for the treatment of rheumatoid arthritis, there is a compelling need to develop alternative therapeutic targets for nonresponders to existing treatments. Soluble receptors occur naturallyin vivo, such as the splice variant of the cell surface receptor for vascular endothelial growth factor (VEGF) – a key regulator of angiogenesis in rheumatoid arthritis. Bioinformatics analyses predict that the majority of human genes undergo alternative splicing, generating proteins – many of which may have regulatory functions. The objective of the present study was to identify alternative splice variants (ASV) from cell surface receptor genes, and to determine whether the novel proteins encoded exert therapeutic activity in anin vivomodel of arthritis.Methods: To identify novel splice variants, we performed RT-PCR using an mRNA pool representing major human tissue types and tumors. Novel ASV were identified by alignment of each cloned sequence to its respective genomic sequence in comparison with full-length transcripts. To test whether these ASV have biologic activity, we characterized a subset of them for ligand binding, and for efficacy in an animal model of arthritis. Thein vivostudy was accomplished using adenoviruses expressing secreted ASV.Results: We cloned 60 novel human ASV from 21 genes, encoding cell surface receptors – many of which are known to be important in the regulation of angiogenesis. The ASV were characterized by exon extension, intron retention and alternative exon utilization. Efficient expression and secretion of selected ASV – corresponding to VEGF receptor type 1, VEGF receptor type 2, VEGF receptor type 3, angiopoietin receptor Tie1, Met (receptor for hepatocyte growth factor), colony-stimulating factor 1 receptor, platelet-derived growth factor receptor beta, fibroblast growth factor receptor 1, Kit, and RAGE – was demonstrated, together with binding to their cognate ligands. Importantly, ASV derived from VEGF receptor type 1 and Tie1, and to a lesser extent from VEGF receptor type 2 and fibroblast growth factor receptor 1, reduced clinical signs of arthritisin vivo. The reduction was paralleled by decreased joint inflammation and destruction.Conclusion: The present study shows that unique ASV derived from receptors that play key roles in angiogenesis – namely, VEGF receptor type 1 and, for the first time, Tie1 – can markedly reduce arthritis severity. More broadly, our results demonstrate that ASV are a source of novel proteins with therapeutic potential in diseases in which angiogenesis and cellular hyperplasia play a central role, such as rheumatoid arthritis.
- Open Access
- 8 December 2004
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (12) , 4079-4080
Reply
- 8 December 2004
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (12) , 4079-4080
Open AccessReply